Literature DB >> 30003585

Proton pump inhibitors and Raynaud's phenomenon: is there a link?

Charles Khouri1,2,3, Bruno Revol1,3, Jean-Luc Cracowski2,3, Matthieu Roustit2,3.   

Abstract

Keywords:  Raynaud's phenomenon; drug safety; proton pump inhibitors

Mesh：

Substances：

Year:  2018        PMID： 30003585      PMCID： PMC6138507          DOI： 10.1111/bcp.13697

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

Review 2.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

3.  Proton pump inhibitors and Raynaud's phenomenon: is there a link?

Authors:  Charles Khouri; Bruno Revol; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2018-07-12       Impact factor: 4.335

4.  Proton Pump Inhibitors Accelerate Endothelial Senescence.

Authors:  Gautham Yepuri; Roman Sukhovershin; Timo Z Nazari-Shafti; Michael Petrascheck; Yohannes T Ghebre; John P Cooke
Journal:  Circ Res       Date:  2016-05-10       Impact factor: 17.367

5.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

6.  Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.

Authors:  Yohannes T Ghebremariam; Paea LePendu; Jerry C Lee; Daniel A Erlanson; Anna Slaviero; Nigam H Shah; James Leiper; John P Cooke
Journal:  Circulation       Date:  2013-07-03       Impact factor: 29.690

7.  Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.

Authors:  Tse-Min Lu; Ming-Yi Chung; Ming-Wei Lin; Chiao-Po Hsu; Shing-Jong Lin
Journal:  Int J Cardiol       Date:  2011-07-26       Impact factor: 4.164

8.  Proton pump inhibitor use represents an independent risk factor for myocardial infarction.

Authors:  Chia-Jen Shih; Yung-Tai Chen; Shuo-Ming Ou; Szu-Yuan Li; Tzeng-Ji Chen; Shuu-Jiun Wang
Journal:  Int J Cardiol       Date:  2014-09-28       Impact factor: 4.164

9.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.

Authors:  Nigam H Shah; Paea LePendu; Anna Bauer-Mehren; Yohannes T Ghebremariam; Srinivasan V Iyer; Jake Marcus; Kevin T Nead; John P Cooke; Nicholas J Leeper
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971
  10 in total
  1 in total

1.  Proton pump inhibitors and Raynaud's phenomenon: is there a link?

Authors:  Charles Khouri; Bruno Revol; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2018-07-12       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.